<DOC>
	<DOCNO>NCT01865448</DOCNO>
	<brief_summary>Comparative , randomize , placebo-controlled , single-centre , single-blind clinical trial ass effectiveness provide additional DHA omega-3 fatty acid supplement increase level pro-resolving anti-inflammatory lipid mediator decrease biological marker chronic inflammation obese patient follow weight-loss programme .</brief_summary>
	<brief_title>Effects DHA Pro-resolving Anti-inflammatory Mediators Obese Patients Undergoing Weight-loss Treatment</brief_title>
	<detailed_description>Will include obese patient ( BMI 30 35 ) follow standardize , multidisciplinary weight-loss programme ( PronoKal® Method ) , consist very-low-calorie diet base protein packet vegetable low glycemic index , natural food gradually reintroduce , accompany physical exercise emotional support . Patients treat acetylsalicylic acid ( ASA ) , non-steroidal anti-inflammatory drug ( NSAIDS ) , corticoids thiazolidinedione antidiabetic drug ( glitazones ) ; patient immune disorder ( rheumatoid arthritis , Lupus , etc . ) and/or inflammatory disease ( ulcerative colitis , Crohn 's disease , etc . ) may alter biological marker inflammation , exclude . Treatment : In addition vitamin oligoelement supplement part standard weight-loss programme , patient receive additional 500 mg/day supplement DHA omega-3 fatty acid capsule form ( study group ) placebo capsule ( control group ) . The follow 6 month patient monitor course 6 control visit : baseline , 7 day , 15 day , 30 day , 60 day 180 day . The main objective ass effectiveness provide additional DHA supplement increase level pro-resolving anti-inflammatory lipid mediator decrease biological marker chronic inflammation obese patient follow weight-loss programme .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Age 18 75 year Obese patient Body Mass Index 30 35 Patients , regardless inclusion study , go follow standardize weightloss programme ( PronoKal® Method ) Patients agree participate sign Informed Consent form Treatment Omega3 fatty acid supplement reason month prior inclusion trial Treatment acetylsalicylic acid ( ASA ) , nonsteroidal antiinflammatory drug ( NSAIDS ) , corticoids thiazolidinedione antidiabetic drug ( glitazones ) Pregnant nurse patient Haemopathy , include clot disorder Treatment dicoumarin anticoagulant ( Sintrom® ) Cancer history cancer receive oncologist 's release Type 1 type 2 diabetes mellitus Immune disorder ( rheumatoid arthritis , lupus , etc . ) and/or inflammatory disease ( ulcerative colitis , Crohn 's disease , etc . ) may alter biological marker inflammation Patients expect attend monitoring visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Docosahexaenoic Acids</keyword>
	<keyword>Fatty Acids , Omega-3</keyword>
	<keyword>Obesity</keyword>
	<keyword>Inflammation</keyword>
</DOC>